Week of December 20th 2021 | Vol. 10, Issue 50
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory
Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse

Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company

Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
Alcami Corporation, a leading pharmaceutical and biotech contract development and manufacturing organization (CDMO), announced today it has completed the acquisition of Masy Systems Inc. (“Masy” or “Masy BioServices”), a preferred provider of cGMP Biostorage and pharma support services. The financial terms of the transaction were not disclosed.

“The acquisition of Masy adds complementary service offerings and further reinforces Alcami’s ambitious growth and expansion initiatives,” commented Patrick D. Walsh, Chairman and CEO of Alcami.

Masy was founded in 1984 by entrepreneurs Laurie and John Masiello and operates three cGMP Biostorage facilities in Massachusetts, all within 1-hour of Boston and Cambridge, with a fourth facility coming online in early 2022. The company offers secure and tightly controlled cGMP temperature storage from -196˚C to 70˚C, including all ICH stability conditions, for various materials including vaccines, biopharmaceuticals, cell banks, tissues, compounds, and medical devices.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
14 transactions totaling $20,657
Supplies, Equipment & Services
31 transactions totaling $286 million
Healthcare IT & Managed Care
9 transactions totaling $4
Healthcare Facilities & Distributors
12 transactions totaling $2,124
Pharma & Biotech
37 transactions totaling $1,203 million
Supplies, Equipment & Services
47 transactions totaling $812 million
Healthcare IT & Managed Care
15 transactions totaling $217 million
Healthcare Facilities & Distributors
4 transactions totaling $40 million
Pharma & Biotech
15 transactions totaling $821 million
Supplies, Equipment & Services
3 transactions totaling $76
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
December 13, 2021 - Fierce Biotech
As was to be expected, mergers and acquisitions in the medtech sector slowed down quite a bit in the first half of 2020 as the COVID-19 pandemic boxed out many elective procedures and regular clinic visits. Less expected, however, was the industry’s meteoric recovery, which saw M&A activity rapidly bounce back to previous levels—and just keep going.

December 14, 2021 - Fierce Healthcare
Insurtech platform HealthCare.com has closed a $180 million funding round for its AI-powered tools that connect consumers to health plans, boosting the company’s valuation to more than $1 billion.

December 14, 2021 - Fierce Pharma
In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent on vaccines and blood plasma products—Vifor’s attractive kidney disease and iron deficiency franchises.

December 15, 2021 - Fierce Healthcare
Cadence, a digital health startup for virtual care and remote patient monitoring, has raised $100 million in a series B funding round led by Coatue Management. The company, which launched just months ago in August with $41 million in funding, provides a remote care platform to help patients manage chronic conditions at home and at scale.
Events Hosted or Attended by Bourne Partners

Dates TBD - Charlotte, NC

January 10-14, 2022 - San Francisco, CA
We are looking for pharma professionals to join our expanding US and UK teams.

November Highlight: TannerGAP Supplies 19,834 Units of Critical Medicines to 33 Countries Around the World
Discover what's possible with Tanner's Global Access Solutions.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.